CURRENT REPORT

Report date: **18.08.2026**
Name of issuing company: **Antibiotice S.A.**
Headquarters: **Iaşi, str. Valea Lupului nr. 1, zip code 707410**
https://www.antibiotice.ro
E-mail: **relatiicuinvestitorii@antibiotice.ro**
Telephone/fax no. : +4**0232 209 000 / +40372 065 633**
Unique registration code in the Trade Register Office: **RO1973096**
No. in the Trade Register: **J1991000285223**
Subscribed and paid-up capital: **67,133,804 LEI**
The regulated market trading on which the securities are issued**: Bucharest Stock Exchange**
Number of shares: **671,338,040**
Number of votes: **671,338,040**
Main characteristics of the securities issued by the company**: nominative shares, nominal value: 0.10 lei**

Important event to be reported:

CONVENING
OF THE ORDINARY GENERAL MEETINGS OF SHAREHOLDERS

The Management Board of Antibiotice S.A. reunited in the meeting on 18.08.2026, as per art. 117 of Law no. 31/1990 and art. 16 of the company's Articles of Incorporation, correlated with Article 186 of ASF Regulation no. 5/2018, convenes on 30.09.2026, the **Ordinary General Meeting of Shareholders** at 10^{00} a.m. at the company's head office in Iasi, Valea Lupului Street no. 1, with the following agenda:

1. The approval of the Financial Report for the first half of 2026, consisting of:
   a. simplified half-yearly financial statements;
   b. half-yearly report of the board of directors;
   c. the declaration of the responsible persons;
   d. the full report of the audit firm.

2. Approval of the allocation of 50% of the net profit for the 2025 financial year, setting the gross dividend at RON 0.019877174 per share, setting 16 October 2026 as the record date for identifying the shareholders entitled to the effects of this resolution, setting 15 October 2026 as the ex-date, and setting 28 October 2026 as the dividend payment commencement date.

3. Approval of the allocation of 90% of the net profit for the 2025 financial year, setting the gross dividend at RON 0.035778913 per share, setting 16 October 2026 as the record date for identifying the shareholders entitled to the effects of this resolution, setting 15 October 2026 as the ex-date, and setting 28 October 2026 as the dividend payment commencement date.

4. The ratification of the Management Board's Decision no. 1 of 25.06.2026, regarding:

- the approval of the increase in the multicurrency, multiproduct, cash and non-cash credit facility, contracted with UniCredit Bank SA from the amount of RON 91,500,000 to the amount of RON 141,000,000.
- the approval/maintenance of the guarantee of the facility mentioned above, in the amount of RON 141,000,000, which will be contracted with UniCredit Bank SA with the following:
  - Mortgage on the current and future accounts opened by Antibiotice SA at UniCredit Bank SA.
- approval of the authorization of Mr. Ioan Nani as General Director to sign on behalf of Antibiotice SA all documents/credit contracts and their accessories, necessary and related to the contracting and implementation of the credit facility in the total amount of RON 141,000,000 from UniCredit Bank SA, as well as all the subsequent additional documents related to the documents/credit contracts and accessories related to this credit.

5. The rectification of the Decision no. 3 of the Ordinary General Meeting of Shareholders dated 06.11.2025, in order to remedy a material error, as follows:
Resolution No. 3 of the Ordinary General Meeting of Shareholders dated November 6, 2025—stating "With the votes 'for' from shareholders representing 100% of the total votes cast, the vacancy of a director position at Antibiotice S.A. is acknowledged"—is rectified to read: "With the votes 'for' from shareholders representing 100% of the total votes cast, the vacancy of the director position held by Mr. Cătălin-Codruț Popescu is acknowledged, effective as of November 6, 2025."

The shareholders registered at the reference date can exercise their right to attend and vote at general meeting directly, by mail or by a representative with special or general power of attorney, according to the article 105 para. 7, of Law 24/2017 on issuers of financial instruments and market operations. The access of shareholders is allowed based on the identity card, special or general power of attorney, special power of attorney authenticated or mandate, for the legal representatives.

The original vote by mail form together with a copy of the identity card for the individual shareholders or any document certifying the capacity of legal representative for the corporate shareholders or statement of accounts shall be sent to the company headquarters until 28.09.2026, 10^{00} a.m.
In accordance with the art. 105 para. (23^3) of Law no. 24/2017 on the issuers of financial instruments and market operations and by applying the provisions of para. (23^1), the "abstention" position adopted by a shareholder regarding the items on the agenda of the General Meeting of Shareholders does not represent an expressed vote.

Starting with 19.08.2026, the special or general power of attorney, the mail voting form, the draft resolutions, as well as the materials and documents which will be the subject of deliberations will be available both in Romanian and English at the company's headquarters (Investor Relations – phone number: +40372.065.570 / +40372.065.583, fax: +40372.065.633, e-mail: relatiicuinvestitorii@antibiotice.ro) and on our company website (www.antibiotice.ro/en/investors/financial-information/archive-of-the-general-meeting-of-shareholders/OGMS 30.09/01.10.2026).

Until 28.09.2026, 10^{00} a.m., the special or general power of attorney shall be submitted in original form, either in English or Romanian language, accompanied by a copy of the identity card or registration certificate of the shareholder represented, at the company's headquarters or sent via e-mail, with extended electronic signature. In the event that a shareholder mandates a credit institution which provides custody services, to attend and vote in the general meetings, only the original special power of attorney is needed accompanied by an original affidavit issued by the credit institution (according to the article 207 of the FSA Regulation no. 5/2018 on issuers of financial instruments and market operations).

One or more shareholders representing, individually or together, at least 5% of the Company`s share capital has/have the right:

a) to introduce new items on the agenda of the General Meetings of Shareholders accompanied by a justification or by draft resolutions proposed for approval by the General Meetings of Shareholders;
b) to submit draft resolutions for new items included or proposed to be added on the agenda of the General Meetings of Shareholders.

The rights specified under the letters a and b can only be exercised in writing, the formulated proposals to be sent by courier services or by electronic means. Shareholders can exercise the rights specified under the letters a and b within 15 days from the date of publication of the Convening Notice in the Official Gazette of Romania.

In cases where the exercise of the right provided for in letter a) determines the modification of the agenda of the General Meeting already communicated to the shareholders, the company will make available a revised agenda, using the same procedure as that used for the previous agenda, before the reference date of the general meeting of shareholders, so that to allow the other shareholders to appoint a representative or, if applicable, to vote by mail.

The company's shareholders can ask questions regarding the items on the agenda of the General Meetings until 30.09.2026, 10^{00} a.m., at the e-mail address: relatiicuinvestitorii@antibiotice.ro.

In all the above cases, with the exception of the special or general power of attorney granted by a shareholder to a credit institution which provides custody services, the legal entity shareholders prove their legal representative status, with the legal representative's identity card together with an ascertaining certificate issued by the Trade register, or any other document issued by a competent authority in the State where the shareholder is legally registered, which certifies the capacity of legal representative. The documents will be presented in original or in copy conforming to the original. The ascertaining certificate or the equivalent document attesting the legal representative capacity of the legal entity shareholder will be issued no later than 30 days before the date of the General Meeting of Shareholders. These documents certifying the capacity of legal representative drawn up in a foreign language, other than English, will be accompanied by a translation in Romanian or in English made by an authorized translator, without being legalized or apostilled (Art. 194 of Regulation 5/2018 on issuers of financial instruments and market operations).

In accordance with art. 198 and art. 199 of Regulation 5/2018 on issuers of financial instruments and market operations, in the case of shareholders who ask questions or make proposals to complete the agenda, they can attest their identity also by submitting the account statement which proves the shareholder status as well as the number of shares held, issued by the central depository or, as the case may be, by the indirect participants who provide custody services (according to art. 146 paragraph 4^1 of Law no. 297/2004).
More detailed information on shareholders rights can be accessed on the company's website (www.antibiotice.ro).

At this General Meeting of Shareholders, all the shareholders registered in the Shareholders Register by the end of 17.09.2026, established as reference date are entitled to attend and vote.

If the statutory quorum is not met for the validity of the deliberations at the first call, the General Meeting shall be rescheduled for 01.10.2026, at 10^{00} a.m. at the same address and with the same agenda.

President of the Management Board,
Ionuț-Sebastian IAVOR